Hederagenin Alleviated Ovariectomy-Induced Bone Loss through the Regulation of Innate Immune Signaling in Mice
Zhitao Yang1,#, Huanyu Cheng1,#, Xinli Liu1, Jie Li1, Xin Ming1, Beibei Li1, Luyao Zhang1, Chunqing MA1, Yi Jiao1, Shenjia Wu1, Ibrar Muhammad Khan2, Guanghua Xiong1, Hongcheng Wang1,*, Yong Liu1,*
BIOCELL, Vol.50, No.1, 2026, DOI:10.32604/biocell.2025.072736
- 23 January 2026
(This article belongs to the Special Issue: Natural Compounds in Metabolic Health: Mechanisms and Applications)
Abstract Objectives: Postmenopausal osteoporosis is the most common form of osteoporosis in clinical practice, affecting millions of postmenopausal women worldwide. Postmenopausal osteoporosis demands safe and effective therapies. This study aimed to evaluate the potential of hederagenin (Hed) for treating osteoporosis and to elucidate its underlying mechanisms of action. Methods: The anti-osteoporotic potential of Hed was assessed by investigating its effects on ovariectomy (OVX)-induced bone loss in mice and on receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast differentiation in RAW264.7 cells. Network pharmacology analysis and molecular docking were employed to identify key targets, which were subsequently validated experimentally. Results:… More >